MedTech Terms
    The authoritative reference
    Back to Clinical Trials & Evidence
    Clinical & TrialsClinical Evidence

    IDE Supplement

    Amendment to an approved Investigational Device Exemption for protocol or device changes.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    An IDE supplement notifies FDA of changes to an approved IDE - including device modifications, protocol amendments, and investigator additions - and may require prior FDA approval depending on significance. 21 CFR 812.35 sets the rules. Changes affecting the validity of data, subject risk, or the scientific soundness of the plan need FDA approval before implementation, while some developmental changes and minor protocol changes can be made with a five-day notice. New investigational sites need IRB approval and must be reported to FDA. Sponsors usually document change significance in a rationale memo.
    What the regulation says
    The FDA, under 21 CFR 812.35, outlines the requirements for Institutional Review Board (IRB) and FDA approval of an Investigational Device Exemption (IDE) application, including modifications and supplements. Sponsors must notify the FDA of changes to an approved IDE, and the need for prior FDA approval depends on the significance of the change to the investigation as detailed in 21 CFR 812.35 (a) and (b).

    What this means in practice

    Significant changes (e.g., risk profile, indication, primary endpoint) require approval before implementation; minor changes can be reported in the annual report.

    Examples

    • A sponsor submits an IDE supplement for a device modification that changes the material of a patient-contacting component, requiring prior FDA approval.
    • An investigator adds a new study site and principal investigator, which is submitted as an IDE supplement for FDA review and approval.
    • A change to the primary efficacy endpoint of a clinical trial necessitates an IDE supplement requiring prior FDA approval before continuing the study.
    Common pitfalls
    • •Failing to distinguish between significant and minor changes can lead to unapproved study modifications and regulatory non-compliance.
    • •Submitting supplements with insufficient data or justification can result in delays and requests for additional information from the FDA.
    • •Not understanding the specific reporting timelines for different types of changes can lead to non-conformance with FDA regulations.
    • •Assuming that all changes can be reported in the annual report without prior FDA review is a common mistake.
    • •Neglecting to update all relevant study documents, such as the IDE application and informed consent forms, after a supplemental approval can create inconsistencies.

    Frequently asked questions

    A significant change, as per 21 CFR 812.35(a), includes modifications that could affect the study's scientific soundness, the rights, safety, or welfare of subjects, or the investigation's design, such as changes in device material, primary endpoint, or patient population.

    Cross-references

    Follows

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Learning paths (1)
    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 2Tier 3Peer-reviewed and registry evidence· 1
    Link health: 3 verified· last checked 2026-06-20
    FDA·1NIH·1ICH·1
    1. 1
      IDE Modifications
      Tier 2 Verified
      FDAfda.gov
    2. 2
      ClinicalTrials.gov
      Tier 3 Verified
      NIHclinicaltrials.gov
    3. 3
      ICH Guidelines
      Tier 2 Verified
      ICHich.org

    Inline markers like [1] jump to the matching reference above.